CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Phase 1positiveCTX310Positive

AI Analysis

Summary

CRISPR Therapeutics presented Phase 1a data for CTX310 at ESC Congress 2026, demonstrating deep and durable ANGPTL3 editing with triglyceride and LDL lowering effects. The late-breaking presentation showed positive early efficacy signals in this gene editing approach for lipid management.

Clinical Trial Data

Phase

Phase 1a

Primary Endpoint

Met

Outcome Details

Deep and durable ANGPTL3 editing with triglyceride and LDL lowering demonstrated

Importance:6/10

Sentiment:

0.70

CRISPRgene editingCTX310ANGPTL3Phase 1a datalipid managementESC Congress 2026

Related Companies

$CRSP

Read the original article

Published by GlobeNewswire Clinical Studies on August 28, 2026 2:31 PM

Read Original